Cerus Corporation

August 4, 2021

Forward Looking Statements

The following presentation contains forward-looking statements concerning Cerus' products, prospects and expected results, including statements relating to Cerus' 2021 annual product revenue guidance, including Cerus' expectations of sequential quarterly revenue growth in 2021 and its expectations for initial and ramping INTERCEPT Fibrinogen Complex product revenue in the second half of 2021; the market potential for INTERCEPT; the American Red Cross' goal of 100% INTERCEPT-treated platelets by 2023; Cerus' prospects for potential profitability and the expected pathway thereto; potential approval of Cerus' 7-day shelf-life label expansion for INTERCEPT platelets and the related expected timing of a PMA supplement submission to the FDA related thereto; the anticipated submission of the fourth CE Mark module for INTERCEPT red blood cells and the anticipated timing thereof; the potential regulatory approval and launch of the INTERCEPT Blood System for red blood cells in Europe and the anticipated timing thereof; Cerus' expectations with respect to enrollment in its ongoing phase 3 studies of the red blood cell system; the PROPOLIS study design; and other statements that are not historical facts. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a) meet its 2021 annual product revenue guidance, (b) effectively launch and commercialize the INTERCEPT Blood System for Cryoprecipitation, (c) grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contribution resulting from its U.S. and European market agreements, (d) realize meaningful and/or increasing revenue contributions from U.S. customers in the near term or at all, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers, including the American Red Cross, may make under Cerus' commercial agreements with these customers, and/or (e) realize any revenue contribution from its pipeline product candidates, whether due to Cerus' inability to obtain regulatory approval of its pipeline programs, or otherwise; risks associated with the ultimate duration and severity of the COVID-19 pandemic and resulting global economic and financial disruptions, and the current and potential future negative impacts to Cerus' business operations and financial results such as the current and potential additional disruptions to the U.S. and EMEA blood supply resulting from the evolving effects of the COVID-19 pandemic; risks associated with Cerus' lack of commercialization experience with **the** INTERCEPT Blood System for Cryoprecipitation and in the United States generally, and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood System in the United States, including as a result of licensure requirements that must be satisfied by U.S. customers prior to their engaging in interstate transport of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi's efforts to assure an uninterrupted supply of platelet additive solution (PAS); risks related to how any future PAS supply disruption could affect INTERCEPT's acceptance in the marketplace; risks related to how any future PAS supply disruption might affect current commercial contracts; risks related to Cerus' ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction, including INTERCEPT Fibrinogen Complex for the treatment and control of bleeding, and the INTERCEPT Blood System is safe, effective and economical; risks related to the uncertain and time-consuming development and regulatory process, including the risks that (a) Cerus will continue to experience delays in successfully initiating, conducting or completing clinical trials as a result of the COVID-19 pandemic, (b) Cerus may be unable to comply with the FDA's post-approval requirements for the INTERCEPT Blood System, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval(s) for the INTERCEPT Blood System, (c) manufacturing site Biologics License Applications necessary for Cerus to begin distributing the INTERCEPT Blood System for Cryoprecipitation may not be obtained in a timely manner or at all, (d) Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the INTERCEPT red blood cell system in a timely manner or at all, (e) Cerus may be unable to obtain a 7-day shelf-life label expansion for INTERCEPT platelets in a timely manner, or at all, (f) Cerus may be unable to meet its enrollment goals for its clinical studies and the patient enrollment may otherwise be delayed or slower than expected, and (g) Cerus may otherwise be unable to obtain the requisite regulatory approvals to advance its pipeline programs and bring them to market in a timely manner or at all; risks associated with Cerus' lack of experience in marketing products directly to hospitals and expertise complying with regulations governing finished biologics; risks associated with the uncertain nature of BARDA's funding over which Cerus has no control as well as actions of Congress and governmental agencies that may adversely affect the availability of funding under Cerus' BARDA agreement and/or BARDA's exercise of any potential subsequent option periods, including in connection with the general economic environment and uncertainty associated with the evolving effects of the COVID-19 pandemic, such that the anticipated activities that Cerus expects to conduct with the funds available from BARDA may be further delayed or halted and that Cerus may not otherwise realize the total potential value under its agreement with BARDA; risks related to product safety, including the risk that the septic platelet transfusions may not be avoidable with the INTERCEPT Blood System; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or continued or more severe weakening in economic conditions resulting from the evolving effects of the COVID-19 pandemic or otherwise in the markets where Cerus currently sells and is anticipated to sell its products; Cerus' reliance on third parties to market, sell, distribute and maintain its products; Cerus' ability to maintain an effective, secure manufacturing supply chain, including the risks that (x) Cerus' supply chain could be negatively impacted as a result of the evolving effects of the COVID-19 pandemic, (y) Cerus' manufacturers could be unable to comply with extensive FDA and foreign regulatory agency requirements, and (z) Cerus may be unable to maintain its primary kit manufacturing agreement and its other supply agreements with its third party suppliers; Cerus' ability to identify and obtain additional partners to manufacture the INTERCEPT Blood System for Cryoprecipitation; risks associated with Cerus' ability to meet its debt service obligations and its need for additional funding; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of Cerus' future capital requirements and its future revenues and other financial performance and results, as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in Cerus' Annual Report on Form 10-K, filed with the SEC on February 25, 2021 and Form 10-Q, filed with the SEC on August 3, 2021. In addition, to the extent that the COVID-19 pandemic adversely affects Cerus' business and financial results, it may also have the effect of heightening many of the other risks and uncertainties described above. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation.

Focused on Safeguarding the Blood Supply

Our Mission

To make the INTERCEPT® Blood System the **standard of care** in transfusion medicine

Pathogen Inactivation/Reduction **Market Leader**

Global sales in **>40 countries**

INTERCEPT® Blood System

- Platelets
- Plasma
- Red Blood Cells*
- Fibrinogen Complex

**In development*

Blood Matters.™

Building Commercial Momentum

2020 Highlights	2021 Outlook
Full year 2020 Product Revenue $91.9 million; +23% year/year	**Full year 2021 Product Revenue Guidance** $118 million - $122 million*
Growth led by **growing U.S. adoption** of INTERCEPT platelets	Represents projected year/year growth of approximately **28% to 33%**
+9% growth in EMEA region led by W. Europe and **adoption of CCP^ related to COVID-19**	Expected growth driven by anticipated **strong U.S. platelet kit demand**
INTERCEPT Fibrinogen Complex (“IFC”) FDA Approval	INTERCEPT Fibrinogen Complex **commercial launch underway**

^COVID-19 Convalescent Plasma
*2021 product revenue guidance provided by Cerus on and as of August 3, 2021. Actual results may differ.

Q2:21 Recap

Trailing Twelve Month Product Revenues



Q2:21 Highlights

- INTERCEPT platelets **rapidly becoming preferred choice** of U.S. blood centers and hospitals
- Robust adoption of INTERCEPT platelets at leading U.S. blood centers, like the American Red Cross, indicates a **powerful endorsement** globally
- **INTERCEPT Fibrinogen Complex launch progressing as planned**; several initial customer contracts signed

Established Moat with Products Addressing Unmet Clinical Needs

INTERCEPT® Blood System Pathogen Reduction System†

>9 million estimated INTERCEPT treated platelet and plasma doses globally[1*]

20 Years of Global Use*

>300 Blood Centers

>40 Countries, 10 standard of care‡

† Data as of June 30, 2021
[1]Dose treated estimated for Platelet and Plasma based on the number of kits sold to date
*Approximate number ‡Standard of Care defined as a majority of the market

Note: Map not representative of regions where INTERCEPT is currently sold or commercially available

Large & Growing Addressable Market Opportunity* for INTERCEPT

Today

Market Penetration:



Current Components:

Platelets: $0.7B

Plasma: $0.4B

IFC: $0.3B

Growth Drivers:

Organic End Market Growth

Continued Penetration into Currently Served Markets

Expansion into Therapeutics

Future



Future Components:

Geographic Expansion with Current Portfolio of Platelets and Plasma

Product Line Extension (Red Blood Cells)

Additional Market Opportunity:

APAC: $0.9B

RBC: $5.0B

Pathogen reduced red blood cells are in development and are not currently licensed for sale in any geography and INTERCEPT Fibrinogen Complex is not licensed in EMEA

*Addressable market derived from published and estimated global blood products volumes using projected average selling prices across global markets.

The Road to Potentially Establishing Standard of Care & Beyond

Over 3 Decades Developing and Delivering Our "Always On" Technology Across the Globe for Blood Components



Global, Growing INTERCEPT Platelet Franchise

Established Leader In EMEA

Belgium, France & Switzerland have transitioned to a 100% INTERCEPT treated platelet supply



Approaching Standard of Care in the U.S.





*Standard of Care defined as a majority of the market

† Est. U.S. market opportunity based on NBCUS platelet data and average selling prices based on varying kit configurations available.

cerus

INTERCEPT Fibrinogen Complex: Focused Commercial Rollout

Initial launch in five states:

California

Florida

Louisiana

Texas

Wisconsin

Product Delivery & Implementation Underway at Initial Sites

CMS granted New Technology Add-On Payment for IFC, effective October 1, 2021

Strong Sales Funnel in Launch States

Large IDN Among Early Adopters

Nationwide Launch Expected in mid-2022

INTERCEPT® Blood System Product Pipeline

Addresses Significant Global Markets & Product Improvements



[1] Phase III acute and chronic anemia studies successfully completed; CE mark submitted
[2] Patient enrollment in the RedeS and ReCePI studies is underway.
[3] Whole blood efforts through separate collaborations with US FDA and Swissmedic
[4] INTERCEPT Fibrinogen Complex U.S. launch underway

Strong & Improving Financial Profile

Sales Mix

>90% recurring revenue business†

Multiple opportunities for growth over the next several years

Anticipated growth across geographic segments

Revenue



Margins & Cash Flow

SG&A leverage opportunities

Mature R&D programs rolling off as launches commence

Focused on achieving potential profitability as top-line growth continues

†Recurring revenue defined as kit sales for product revenues during 1H:21
*2021 Product revenue guidance provided by Cerus on and as of August 3, 2021. Actual results may differ.

cerus

A leader in the critical field of **blood safety and availability.**

Proprietary and proven pathogen reduction technology is an integral part of blood safety policy in the U.S. helping to potentially **create a new standard of care** in blood safety.

An industry leader with the **only FDA-approved product for pathogen reduced platelets in the U.S.**

Financially disciplined.

Cerus Corporation

Investor Relations

IR@cerus.com

(925) 288-6137